Long-Term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD

AimShort-term use of pemafibrate (PEM), a selective modulator of peroxisome proliferator-activated receptor alpha, has been reported to improve abnormal liver function in patients with nonalcoholic fatty liver disease with hypertriglyceridemia (HTG-NAFLD). This study aimed to clarify the effects and...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Takanobu Iwadare, Takefumi Kimura, Hideo Kunimoto, Taiki Okumura, Shun-Ichi Wakabayashi, Hiroyuki Kobayashi, Yuki Yamashita, Ayumi Sugiura, Naoki Tanaka, Takeji Umemura
Format:	Artigo
Sprog:	Inglês
Udgivet:	Frontiers Media S.A. 2024-05-01
Serier:	Frontiers in Endocrinology
Fag:	non-alcoholic fatty liver disease hypertriglyceridemia pemafibrate selective PPARα modulator body composition analysis treatment response
Online adgang:	https://www.frontiersin.org/articles/10.3389/fendo.2024.1329294/full
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!